Department of Cell Biology, Peking University Health Science Center, Beijing, China.
Int J Gynecol Cancer. 2010 Apr;20(3):316-22. doi: 10.1111/IGC.0b013e3181d0b02d.
LyGDI is an inhibitor of Rho protein activation by blocking its transformation between guanosine 5'-diphosphate- and guanosine 5'-triphosphate-bound states. The aim of this study was to investigate the usefulness of LyGDI as a biomarker for the detection of ovarian cancer, and its specificity and sensitivity were compared with those of cancer antigen 125 (CA125).
The serum levels of LyGDI were determined by enzyme-linked immunosorbent assay in 42 patients with ovarian disease, including 30 ovarian cancers and 12 benign ovarian lesions, and 76 healthy controls. The expression of LyGDI was also evaluated by immunohistochemical staining in resected ovarian tissues of these patients.
The serum LyGDI level of cancers was significantly greater than those of the benign and healthy groups (P = 0.002 and P < 0.0001, respectively), whereas no difference was observed between the benign and control groups (P = 0.889). Based upon receiver operating characteristic curve analysis, LyGDI levels were able to distinguish ovarian cancer from benign ovarian disease (P = 0.0001) and healthy control (P < 0.0001; areas under the receiver operating characteristic curves, 0.876 and 0.833, respectively). For ovarian cancers, 83.3% (25/30) or 80.0% (24/30) was identified by serum LyGDI (> or = 1.5 ng/mL) alone or by CA125 (>35 U/mL) alone. It is of particular importance to note that all cancer patients were identified by use of both markers, and the specificity was 83.3% for the benign group. Moreover, in early-stage cancers, 88.9% (8/9) had elevated serum LyGDI levels as compared with 44.4% (4/9) elevation of CA125 levels (P = 0.125). Immunohistochemical staining confirmed the expression of LyGDI on cancerous epithelial cells other than benign ovarian epithelium.
These results suggest that LyGDI has significant potential as a marker for detection of ovarian cancer in the patients with ovarian enlargement, including detection of early-stage cancers.
LyGDI 是一种 Rho 蛋白激活抑制剂，通过阻止其在鸟苷 5'-二磷酸和鸟苷 5'-三磷酸结合状态之间的转化来实现。本研究旨在探讨 LyGDI 作为卵巢癌检测标志物的有用性，并比较其与癌症抗原 125（CA125）的特异性和敏感性。
采用酶联免疫吸附试验检测 42 例卵巢疾病患者（包括 30 例卵巢癌和 12 例良性卵巢病变）和 76 例健康对照者血清 LyGDI 水平。采用免疫组织化学染色法检测这些患者卵巢组织中 LyGDI 的表达。
癌症患者血清 LyGDI 水平明显高于良性和健康组（P = 0.002 和 P < 0.0001），而良性和健康组之间无差异（P = 0.889）。基于受试者工作特征曲线分析，LyGDI 水平能够区分卵巢癌与良性卵巢疾病（P = 0.0001）和健康对照组（P < 0.0001；受试者工作特征曲线下面积分别为 0.876 和 0.833）。对于卵巢癌患者，单独使用血清 LyGDI（>或= 1.5ng/mL）或 CA125（>35U/mL）可分别识别 83.3%（25/30）或 80.0%（24/30）的患者。值得注意的是，使用两种标志物可识别所有癌症患者，且良性组的特异性为 83.3%。此外，在早期癌症患者中，与 CA125 水平升高的 44.4%（4/9）相比，血清 LyGDI 水平升高的比例为 88.9%（8/9）（P = 0.125）。免疫组织化学染色证实 LyGDI 在癌性上皮细胞而非良性卵巢上皮细胞中有表达。
这些结果表明，LyGDI 作为卵巢增大患者（包括早期癌症患者）卵巢癌检测标志物具有重要潜力。
